FDA advisory group votes against COVID-19 vaccine booster dose
The vote in favor of boosters came after the committee overwhelmingly rejected recommending the extra shots for the general population.
Erika EdwardsA Food and Drug Administration advisory panel overwhelmingly voted in favor of Pfizer-BioNTech's COVID-19 booster shots on Friday for people ages 65 and up as well as those at high risk of severe illness, after initially rejecting boosters for everyone ages 16 and up.
The unanimous vote in favor of boosters was the second vote called by the Vaccine and Related Biological Products Advisory Committee, or VRBPAC, during its meeting Friday.The committee of outside experts was first asked whether a third shot of Pfizer's vaccine would be safe and effective for everyone ages 16 and older. Members overwhelmingly voted against that recommendation, citing concerns about the level of evidence showing the boosters are safe for younger people.
“We’re being asked to approve this as a three-dose vaccine for people 16 years of age and older, without any clear evidence if the third dose for a younger person when compared to an elderly person is of value,” said committee member Dr. Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia. headtopics.com
Sept. 17, 202101:58Such feedback led to further debate among the committee members about specific age groups or populations that may be most appropriate for a third dose of vaccine. The panel subsequently narrowed the recommendation to those over age 65 and anyone at higher risk for severe illness.
People at high risk of exposure at work, such as health care workers and teachers, will likely also be eligible for a booster dose.The panel's recommendation will now go to the FDA, which is not required to follow VRBPAC's vote, but usually does.
Though three COVID vaccines are in use, Friday’s vote focused on the Pfizer vaccine only, and would only apply to those who originally received the Pfizer shots. It does not apply to people who have received the Moderna or Johnson & Johnson vaccines.
The panel's ultimate recommendation was a measured response and"appropriate based on the data that was provided," said Dr. Richard Besser, president of the Robert Wood Johnson Foundation and former acting Centers for Disease Control and Prevention director. headtopics.com
Still, the decision could put the FDA at odds with Biden administration officials who have beenpushing to begin giving out booster shotsto the general population starting the week of Sept. 20, essentially starting the countdown for the FDA and the CDC to act.
The booster question will now go to a group of advisers to the CDC, which will take up the issue in a two-day meeting next week.Members of the FDA advisory committee struck a skeptical tone during the meeting Friday, questioning Pfizer’s conclusions that immunity is waning to the point that vaccinated people of all ages need an additional dose to protect against hospitalization and death six months after they’ve received their second dose.
Representatives from Pfizer said the need for a booster is based on data from Israel, which showed that severe cases increased tenfold from July to August, despite the fact that 60 percent of the population there was fully vaccinated.But data from the United States, presented by the CDC, found the vaccines continued to provide high protection against severe disease, hospitalization and death.
Dr. Sara Oliver, an epidemic intelligence service officer at the CDC, noted that Israel and the U.S have different definitions for what’s considered severe disease. In Israel, she said, it is defined as lower oxygen levels and an elevated respiratory rate. In the U.S., severe disease refers to hospitalization or death. headtopics.com
The two countries also vary differently in population, pandemic and acceptance of vaccines. “You really have a very different situation in Israel than what we are facing here in the US at this point in time,” said Dr. Archana Chatterjee, an expert in pediatric infectious diseases at Rosalind Franklin University in Chicago.
The FDA advisory committee also raised questions about the safety of an additional dose, particularly in regard to the risk ofmyocarditis, a rare side effect that’s been seen primarily in males younger than 30.Israeli researchers reported Friday that among 2.8 million people who had been given a third dose, only one case of myocarditis had been reported. However, it’s only been two weeks since younger adults have been given a booster in Israel, and may not reflect the full scope of cases.
“I have a serious concern about myocarditis and young people,” Dr. James Hildreth, CEO of Meharry Medical College in Nashville, Tennessee, and a member of the advisory committee. “The booster shots induce a very strong response that is going to amplify the risk for myocarditis in those individuals.”
Surgeon General Vivek Murthy said earlier Friday during a White House COVID task force briefing that the booster plan was always contingent upon the two agencies’ decision.“We have always said that this initial plan would be contingent on the FDA and the CDC’s independent evaluation,” he said. “We will follow that evaluation and their recommendations, we will make sure our final plan reflects it.”
Pfizer’s vaccine, sold under the brand name Comirnaty, receivedfull FDA approvalfor ages 16 and older in August. This means doctors have the freedom to administer a third dose to patients they deem necessary for the shot; however physicians — and especially retail pharmacies and public health departments where the majority of COVID vaccines are administered — are sure to pay close attention to the outcome of Friday’s meeting.
The FDA previously OK’d an additional shot for people with, who did not react strongly enough to the initial doses of the vaccines. Read more: »
Lucy: The First Mission to Jupiter’s Trojans
NASA.gov brings you the latest images, videos and news from America's space agency. Get the latest updates on NASA missions, watch NASA TV live, and learn about our quest to reveal the unknown and benefit all humankind.
They dod read the science - and not just that paid for by Pfizer It means they don’t know what the hell is going on. This should make everyone feel safe about what they know about the long term side effects! Good luck to all that got the jab!!
COVID-19 Vaccines Won’t Affect Your Sexual Performance, but COVID-19 MightJust in case you were wondering. I like your choice of that photo. Very fitting. mood😑
FDA Panel Weighs Covid-19 Booster Shots as Health Officials Debate NeedThe Biden administration’s push to introduce widespread vaccine boosters faces a test as a Food and Drug Administration advisory panel meets to weigh evidence on the extra shots, a topic that has divided federal health officials. good luck Clown world What is there to weigh here. Either the science supports it or it doesn’t
FDA advisers vote to oppose Pfizer/BioNTech COVID-19 vaccine boosterA panel of outside advisers to the U.S. Food and Drug Administration on Friday voted against approval of a booster dose of the Pfizer Inc /BioNTech SE COVID-19 vaccine for people aged 16 and older. Wrong headline here. They voted against it for people as young as 16. They have not yet voted on it for adults 60 and older and those with compromised immunity.
Coronavirus update: FDA booster meeting and Covid-19 vaccine newsThe Food and Drug Administration's advisory committee is meeting today to discuss booster doses of coronavirus vaccine. Follow here for the latest news. 60+ should get 3rd shot. Period. This is NOT following the science...
FDA panel is first key test for Biden COVID-19 booster planGovernment advisers are debating whether to recommend extra doses of the Pfizer vaccine, a key step toward the Biden administration's plan to dispense COVID-19 booster shots. Scientists have been divided over the need for boosters and who should get them. The Delta variant was from December, 2020. This should be a no-brainer right now. Think more as clinicians and practitioners than researchers. Science is now a debate and not based off evidence or facts. Let that sink in.
FDA Questions Need For Pfizer Covid-19 Booster Shot Ahead Of Vote FridayScientists at the FDA said Pfizer’s Covid-19 vaccine seems to last long enough that a booster shot may not add much protection